Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr Siegel on the Preliminary Use of Mezigdomide in Relapsed/Refractory Myeloma

December 9th 2024

David Samuel Dicapua Siegel, MD, discusses preliminary findings from the phase 1/2 CA057-003 trial of mezigdomide in relapsed/refractory multiple myeloma.

Daratumumab Significantly Improves PFS, Extends OS in Smoldering Myeloma

December 8th 2024

Subcutaneous daratumumab reduced the risk for disease progression or death vs active monitoring in intermediate- or high-risk smoldering multiple myeloma.

Dr Kaddoura on Genomic Determinants of Outcomes in IGH/CCND1+ Myeloma Treated With Venetoclax

December 8th 2024

Marcella Ali Kaddoura, MD, discusses genomic determinants of clinical outcomes in myeloma with t(11;14)(CCND1;IGH) treated with venetoclax.

D-VRd Deepens MRD Responses in Transplant-Ineligible or -Deferred Newly Diagnosed Myeloma

December 8th 2024

Daratumumab plus VRd improved MRD responses and progression-free survival in transplant-ineligible or -deferred newly diagnosed multiple myeloma.

Drs Baljevic and Cortes Preview Upcoming Studies and Emerging Data From ASH 2024

December 6th 2024

Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.

Dr Kumar on Key Treatment Considerations for Myeloma Following NCCN Guideline Updates

December 4th 2024

Shaji Kumar, MD, discusses notable therapy considerations for multiple myeloma following the 2024/early 2025 NCCN guidelines update.

The OncFive: Top Oncology Articles for the Week of 11/24

November 30th 2024

Belantamab mafodotin is under FDA review in multiple myeloma, and Suneel Kamath, MD, highlights pancreatic cancer awareness month.

Dr Kumar on the 2024/2025 NCCN Treatment Updates in Myeloma

November 27th 2024

Shaji Kumar, MD, discusses 2024 updates made to the NCCN guidelines for multiple myeloma treatment, as well as the first 2025 updates.

Health Canada Approves Cilta-Cel for Relapsed/Lenalidomide-Refractory Myeloma

November 26th 2024

Health Canada has approved cilta-cel for use in patients with relapsed/lenalidomide-refractory multiple myeloma following 1 to 3 prior lines of therapy.

FDA Accepts BLA for Belantamab Mafodotin–Based Combos in R/R Myeloma

November 25th 2024

The FDA accepted a BLA for 2 belantamab mafodotin–based combinations in relapsed/refractory multiple myeloma.

Bispecific Antibodies and CAR T-Cell Therapies Continue to Reshape Myeloma Treatment Landscape

November 22nd 2024

Syed Abbas Ali, MBBS, discusses how CAR T-cell therapies and bispecific antibodies have altered treatment in relapsed/refractory multiple myeloma.

The OncFive: Top Oncology Articles for the Week of 11/10

November 16th 2024

New datopotamab deruxtecan BLA in NSCLC filed to FDA, radiopharmaceutical meets rPFS end point in PSMA+ prostate cancer, and more.

Isatuximab Plus VRd Earns CHMP Recommendation for Newly Diagnosed, Transplant-Ineligible Myeloma

November 15th 2024

The CHMP has recommended the EU approval of isatuximab plus VRd for newly diagnosed, transplant-ineligible multiple myeloma.

Belantamab Mafodotin Plus Bortezomib/Dexamethasone Extends OS in R/R Myeloma

November 14th 2024

Belantamab mafodotin plus bortezomib and dexamethasone met the key secondary end point of OS in relapsed/refractory multiple myeloma in the DREAMM-7 study.

Dr Sborov on CAR T-Cell Therapy–Specific Long-Term Treatment Effects in Myeloma

November 11th 2024

Douglas W. Sborov, MD, MS, discusses long-term treatment outcomes for patients with myeloma who received CAR T-cell therapy vs another treatment option.

Dr Dimopoulos on Efficacy Findings From the DREAMM-8 Trial in Multiple Myeloma

November 9th 2024

Meletios Dimopoulos, MD, discusses the design of and findings from the DREAMM-8 trial investigating BPd in patients with multiple myeloma.

FDA, EMA Receive Applications for Subcutaneous Daratumumab in High-Risk Smoldering Myeloma

November 8th 2024

Applications have been submitted to the FDA and EMA seeking approval for daratumumab in high-risk smoldering multiple myeloma.

Dr Delforge on the Rationale for CARTITUDE-4 in Lenalidomide-Refractory Myeloma

November 7th 2024

Michel Delforge, MD, PhD, discusses the rationale for conducting the CARTITUDE-4 trial investigating cilta-cel in lenalidomide-refractory multiple myeloma.

FDA Grants Orphan Drug Designation to LBL-034 for Multiple Myeloma

November 6th 2024

The FDA has granted orphan drug designation to LBL-034 for the treatment of patients with multiple myeloma.

Notable 2024/Early 2025 Multiple Myeloma NCCN Guideline Updates Feature Quadruplets and More

November 6th 2024

Shaji Kumar, MD, details key updates/revisions made to the multiple myeloma NCCN guidelines in 2024 and the first version of the 2025 guidelines.